Chulabhorn Research Institute has successfully developed therapeutic drugs for breast cancer and is


          The Chulabhorn Research Institute, under the guidance of Professor Dr. HRH Princess Chulabhorn Walailakin, has successfully developed a biopharmaceutical product called Trastuzumab, the first monoclonal antibody capable of treating breast cancer. Trastuzumab is the first Thai biopharmaceutical innovation conceived and conducted by local researchers without purchasing or transferring technology from abroad. The research was conducted with international standards of quality control and monitoring in all stages of production, which finally resulted in an industrial volume of the medication.

Page view : 25